Table 2.
Minimum inhibitory concentration (μg/mL) of NF-κB inhibitors IMD0354 against vancomycin-resistant Staphylococcus aureus (VRSA) and vancomycin-intermediate Staphylococcus aureus (VISA) clinical strains.
| IMD0354 | Vancomycin | |||
|---|---|---|---|---|
| Strain | MIC | MBC | MIC | MBC |
| VRS1 | 0.06 | 2 | >64 | >64 |
| VISA 215 | 0.25 | 0.5 | 8 | 8 |
| VISA 216 | 0.06 | 2 | 8 | 16 |
| VISA 217 | 0.125 | 0.5 | 8 | 8 |
| VISA 218 | 0.06 | 0.5 | 8 | 8 |
| VISA 219 | 0.06 | 1 | 8 | 16 |
| VISA 220 | 0.25 | 2.0 | 8 | 16 |
| VISA 221 | 0.06 | 1.0 | 8 | 8 |
| VISA 222 | 0.125 | 2.0 | 8 | 8 |
| VISA 223 | 0.125 | 1.0 | 4 | 8 |
| VISA 224 | 0.25 | 2 | 4 | 16 |
| VISA 225 | 0.125 | 0.25 | 4 | 8 |
| VISA 226 | 0.06 | 0.125 | 4 | 4 |
| VISA 227 | 0.25 | 0.5 | 8 | 8 |
| VISA 228 | 0.125 | 0.5 | 4 | 8 |